Jung Hyun-Min, Paik Jinhui, Lee Minsik, Kim Yong Won, Kim Tae-Youn
Department of Emergency Medicine, Inha University Hospital, College of Medicine, Inha University, 27, Inhang-ro, Jung-gu, Incheon 22332, Republic of Korea.
Department of Emergency Medicine, Dongguk University Ilsan Hospital, College of Medicine, Dongguk University, Goyang 10326, Republic of Korea.
J Clin Med. 2024 Apr 16;13(8):2306. doi: 10.3390/jcm13082306.
: The Tokyo Guidelines 2018 (TG2018) is a scoring system used to recommend the clinical management of AC. However, such a scoring system must incorporate a variety of clinical outcomes of acute cholangitis (AC). In an emergency department (ED)-based setting, where efficiency and practicality are highly desired, clinicians may find the application of various parameters challenging. The neutrophil-to-lymphocyte ratio (NLR) and blood urea nitrogen-to-albumin ratio (BAR) are relatively common biomarkers used to assess disease severity. This study evaluated the potential value of TG2018 scores measured in an ED to predict a variety of clinical outcomes. Furthermore, the study also compared TG2018 scores with NLR and BAR scores to demonstrate their usefulness. : This retrospective observational study was performed in an ED. In total, 502 patients with AC visited the ED between January 2016 and December 2021. The primary endpoint was to evaluate whether the TG2018 scoring system measured in the ED was a predictor of intensive care, long-term hospital stays (≥14 days), percutaneous transhepatic biliary drainage (PTBD) during admission care, and endotracheal intubation (ETI). : The analysis included 81 patients requiring intensive care, 111 requiring long-term hospital stays (≥14 days), 49 requiring PTBD during hospitalization, and 14 requiring ETI during hospitalization. For the TG2018 score, the adjusted OR (aOR) using (1) as a reference was 23.169 (95% CI: 9.788-54.844) for (3) compared to (1). The AUC of the TG2018 for the need for intensive care was 0.850 (95% CI: 0.815-0.881) with a cutoff of >2. The AUC for long-term hospital stays did not exceed 0.7 for any of the markers. the AUC for PTBD also did not exceed 0.7 for any of the markers. The AUC for ETI was the highest for BAR at 0.870 (95% CI: 0.837-0.899) with a cutoff value of >5.2. : The TG2018 score measured in the ED helps predict various clinical outcomes of AC. Other novel markers such as BAR and NLR are also associated, but their explanatory power is weak.
《2018年东京指南》(TG2018)是一种用于推荐急性胆管炎(AC)临床管理的评分系统。然而,这样的评分系统必须纳入急性胆管炎的各种临床结局。在急诊科(ED)环境中,效率和实用性备受关注,临床医生可能会发现应用各种参数具有挑战性。中性粒细胞与淋巴细胞比值(NLR)和血尿素氮与白蛋白比值(BAR)是用于评估疾病严重程度的相对常见的生物标志物。本研究评估了在急诊科测量的TG2018评分预测各种临床结局的潜在价值。此外,该研究还将TG2018评分与NLR和BAR评分进行比较,以证明它们的有用性。
这项回顾性观察研究在急诊科进行。2016年1月至2021年12月期间,共有502例AC患者就诊于该急诊科。主要终点是评估在急诊科测量的TG2018评分系统是否是重症监护、长期住院(≥14天)、入院治疗期间经皮经肝胆道引流(PTBD)和气管插管(ETI)的预测指标。
分析包括81例需要重症监护的患者、111例需要长期住院(≥14天)的患者、49例住院期间需要PTBD的患者以及14例住院期间需要ETI的患者。对于TG2018评分,以(1)为参照,(3)与(1)相比的调整后比值比(aOR)为23.169(95%置信区间:9.788 - 54.844)。对于需要重症监护的情况,TG2018的曲线下面积(AUC)为0.850(95%置信区间:0.815 - 0.881),临界值>2。对于长期住院,任何标志物的AUC均未超过0.7。对于PTBD,任何标志物的AUC也未超过0.7。对于ETI,BAR的AUC最高,为0.870(95%置信区间:0.837 - 0.899),临界值>5.2。
在急诊科测量的TG2018评分有助于预测AC的各种临床结局。其他新型标志物如BAR和NLR也有相关性,但其解释力较弱。